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The 8
th
 edition of the American Joint Committee on Cancer (AJCC) melanoma staging took effect in 49 
January 2018 (1). In this new edition, classification of T1 melanomas was modified, whereby mitotic 50 
rate is no longer a staging criterion and 0.8mm not 1.0mm becomes the thickness boundary 51 
between T1a and T1b (1).  In order to better appreciate specific consequences of the new system for 52 
patients with early melanoma, we assessed disease-free survival (DFS) as a surrogate of overall 53 
survival in patients with early invasive melanoma who were down-staged from T1b to T1a under the 54 
8
th
 edition.  55 
Study participants were enrolled in an ongoing follow-up study of high-risk primary melanoma at 56 
time of their diagnosis with T1b-T4b cutaneous melanoma according to 7
th
 edition AJCC staging, 57 
from 2010 to 2014 in Queensland, Australia (2). Two institutional Human Ethics Committees 58 
approved the study. Patients aged over 16 were recruited via public hospitals, private clinics and 59 
pathology services. Clinical and patient information was collected at diagnosis via questionnaires and 60 
histopathology reports provided information on tumour characteristics. Melanoma recurrences 61 
were self-reported through follow-up questionnaires administered every six months and confirmed 62 
by histopathology and imaging.  63 
T1b tumors were re-classified using the 8
th
 AJCC staging edition and distributions of patient and 64 
tumor characteristics were analysed according to AJCC edition. Three-year DFS was obtained by 65 
Kaplan–Meier analysis for patients who remained T1b and those down-staged to T1a, and repeated 66 
while stratifying by mitotic rate. 67 
Of 208 patients with 7
th
 edition T1b melanomas, 111 (53%) remained T1b and 97 (47%) decreased to 68 
T1a under the 8
th
 edition (Table 1). Patients down-staged to T1a were diagnosed with melanomas 69 
<0.8mm thick, without ulceration and with mitotic rates 1-3/mm
2
 (n=87) and >3/mm
2
 (n=10).  Five 70 
recurrences occurred within 3 years of diagnosis in this down-staged subgroup, equating to an 71 
overall DFS of 95%. When stratified by mitotic rate, patients with 1-3 mitoses/mm
2
 and >3 72 
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mitoses/mm
2
, had a 96% and 80% DFS respectively. The DFS of patients down-staged to T1a under 73 
the 8th AJCC edition remains comparable to the 93% DFS of T1b melanomas. 74 
Our early results suggest that mitoses remain an important prognostic feature of thin melanomas, 75 
the majority of melanomas diagnosed today (3). Our results also estimate that nearly half of 7th 76 
edition T1b tumors will be down-staged to T1a with the 8
th
 edition, compared to a suggested 8% up-77 
staging of T1a to T1b (4). The main limitations of this study are short follow-up and a relatively small 78 
study population. Although we do not know DFS for all T1a tumors, we do know 5-year cause-79 
specific survival for T1a melanoma is around 99% (5).  80 
The subset of patients with 8
th
 edition T1a melanomas with mitoses may not share the same 81 
prognosis as those without mitoses. While the 8
th
 edition AJCC classification brings new clarity to 82 
melanoma staging overall, if our findings are corroborated in a larger patient cohort, clinicians will 83 
need to be alerted to the higher risk of disease recurrence of this patient subgroup. Without specific 84 
flagging of these higher-risk patients, their poorer outcomes will be indistinguishable, diluted by 85 
better outcomes among the low-risk majority of patients with T1a melanomas without mitoses.    86 
  87 
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Table 1: Patient characteristics by AJCC edition and tumor stage  88 
 7
th
 edition  8
th
 edition  
 T1b 
 
N (%) 
Down-staged 
to T1a 
N (%) 
Remained 
T1b 
N (%) 
 
p-value
3 
Total  208 (100) 97 (47) 111 (53)  
Age (years) 
    <65  
    ≥65  
 
117 (56) 
91 (44) 
 
55 (57) 
42 (43) 
 
62 (56) 
49 (44) 
 
0.90
 
 
Sex 
    Male 
    Female 
 
96 (46) 
112 (54) 
 
44 (45) 
53 (55) 
 
52 (47) 
59 (53) 
 
0.83
 
Subtype  
    SSM
1
    
    Nodular  
    Other  
 
126 (60) 
14 (7) 
68 (33) 
 
66 (62) 
5 (5) 
32 (33) 
 
66 (60) 
9 (8) 
36 (32) 
 
0.70 
Body site  
    Head/neck  
    Other 
 
32 (15) 
176 (85) 
 
12 (12) 
85 (88) 
 
20 (18) 
91 (82) 
 
0.26 
Personal history 
    No 
    Yes 
 
176 (85) 
32 (15) 
 
85 (88) 
12 (12) 
 
91 (82) 
20 (18) 
 
0.26 
SLNB
2
 
    No  
    Yes  
 
165 (82) 
36 (18) 
 
90 (93) 
7 (7) 
 
82 (74) 
29 (26) 
 
0.0002 
SLNB positivity 
    No  
    Yes 
 
35 (97) 
1 (3) 
 
7 (100) 
0 (0) 
 
28 (96) 
1 (4) 
 
0.81
4 
 89 
1- Superficial spreading melanoma 90 
2- Sentinel lymph node biopsy 91 
3- Chi-squared Test 92 
4- Fisher’s Exact Test 93 
 94 
  95 
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